Oligodendroglial Involvement in Progressive Supranuclear Palsy describes the role of oligodendrocytes and their precursors in PSP pathogenesis. While PSP is primarily considered a tauopathy affecting neurons, emerging evidence demonstrates significant oligodendroglial pathology that contributes to white matter degeneration, myelin dysfunction, and disease progression.
Oligodendrocytes are the myelin-producing cells of the central nervous system:
- Myelination: Each oligodendrocyte extends processes to myelinate multiple axons
- Metabolic support: Provide lactate and pyruvate to neurons through oligodendrocyte-neuron lactate shuttle
- Ion homeostasis: Buffer extracellular potassium during neuronal activity
- Axonal maintenance: Support long-term axonal integrity
| Subtype |
Location |
Function |
PSP Vulnerability |
| Myelinating OLs |
White matter |
Produce myelin |
High |
| OPCs |
Gray/white matter |
Proliferate, differentiate |
Moderate |
| OL precursors |
Perivascular |
Monitor, repair |
Low |
Coiled bodies represent a hallmark of oligodendroglial tau pathology in PSP. These filamentous inclusions were first described by Kato and colleagues in 1992 and remain a critical diagnostic feature. Unlike the neurofibrillary tangles found in neurons, coiled bodies exhibit distinct morphological characteristics:
Ultrastructural Features:
- Composed of 15-20 nm straight filaments arranged in parallel bundles
- Associated with ribosome-like particles
- Often located in the perinuclear region
- May extend into oligodendrocyte processes
Biochemical Composition:
- Predominantly 4-repeat tau isoforms (4R tau)
- Hyperphosphorylated tau at multiple sites (Ser202, Thr205, Ser396, Ser404)
- Tau C-terminal fragments truncated at Asp421
- Co-localization with ubiquitin and p62
Regional Distribution:
- Highest density in globus pallidus and subthalamic nucleus
- Significant burden in cerebral peduncle and pontine base
- Correlation with neuronal neurofibrillary tangle density
- Progressive spread following white matter tracts
The preferential accumulation of 4R tau in oligodendrocytes raises important questions about isoform-specific vulnerability:
4R Tau Dominance:
- Normal adult brain expresses equal 1:1 ratio of 3R and 4R tau
- PSP oligodendrocytes show 4R:3R ratio of approximately 3:1
- May reflect differential splicing regulation or clearance mechanisms
- 4R tau forms more stable aggregates under cellular stress
Molecular Mechanisms:
- Alternative splicing of MAPT exon 10
- Impaired autophagy of 4R tau species
- Differential exosome packaging of tau isoforms
- Altered neuronal-oligodendrocyte tau transfer
While both PSP and Multiple System Atrophy (MSA) involve oligodendroglial pathology, the underlying mechanisms differ substantially:
| Aspect |
PSP |
MSA |
| Primary protein |
Tau (4R) |
α-synuclein |
| Inclusion type |
Coiled bodies |
Glial cytoplasmic inclusions (GCIs) |
| Neuronal involvement |
Primary |
Secondary |
| Oligodendroglial role |
Secondary target |
Primary driver |
| Myelin loss |
Secondary to tau |
Primary pathology |
¶ GCI vs. Coiled Body Pathology
Glial Cytoplasmic Inclusions (MSA):
- Predominantly cytoplasmic (vs. coiled body perinuclear)
- Longer filamentous structure (100-200 nm vs. 15-20 nm)
- Composed of α-synuclein (not tau)
- Associated with mitochondrial dysfunction
- More severe demyelination
Coiled Bodies (PSP):
- Perinuclear filamentous inclusions
- Tau-positive, α-synuclein negative
- Associated with myelin protein alterations
- Less severe demyelination than MSA
The oligodendroglial pathology patterns correlate with distinct clinical presentations:
MSA-Predominant Motor Symptoms:
- Early autonomic dysfunction (orthostatic hypotension, urinary dysfunction)
- Rapid disease progression
- Prominent parkinsonism unresponsive to levodopa
PSP-Dominant Features:
- Early postural instability and falls
- Vertical gaze palsy
- Pseudobulbar affect
- Cognitive frontal dysfunction
White matter degeneration in PSP follows characteristic patterns that reflect both oligodendroglial vulnerability and axonal tract organization:
Superior Cerebellar Peduncle:
- Most consistently affected tract in PSP
- Contributes to ataxia and gait disturbance
- Early involvement detectable on diffusion MRI
- Crossed cerebellar diaschisis due to dentate nucleus involvement
Corpus Callosum:
- Particularly affects anterior and mid-body regions
- Contributes to interhemispheric transfer deficits
- Correlates with frontal lobe dysfunction
- thinning of 40-60% in PSP vs. controls
Internal Capsule:
- Posterior limb involvement affects corticospinal tracts
- Contributes to axial rigidity
- Anterior limb affects frontostriatal connections
Cerebral Peduncle:
- Severe degeneration of corticobulbar fibers
- Contributes to dysarthria and dysphagia
- Pigment loss in substantia nigra correlates
White matter degeneration follows predictable patterns in PSP:
- Stage 1: Subthalamic nucleus and globus pallidus
- Stage 2: Extension to cerebral peduncle and pontine base
- Stage 3: Corpus callosum involvement
- Stage 4: Cerebral white matter radiations
- Stage 5: Spinal cord tracts
Oligodendrocyte Susceptibility:
- Regional variation in oligodendrocyte subtype distribution
- Differential iron accumulation across regions
- Variable metabolic demands of different tracts
- Differential expression of tau aggregation modifiers
Axonal Contributions:
- Dying-back axonopathy secondary to neuronal loss
- Primary axonal pathology in corticospinal tracts
- Transport deficits preceding structural changes
Given the significant oligodendroglial involvement, myelin-targeted therapies represent a promising approach:
Remyelination Promotion:
- Clemastine: Antihistamine with pro-myelinating properties
- Currently in clinical trials for multiple sclerosis
- May benefit PSP patients with preserved OPCs
- Dose-limiting sedation
- Opicinumab: Anti-LINGO-1 antibody
- Promotes OPC differentiation
- Phase 2 trials showed mixed results in MS
- Potential for PSP with appropriate patient selection
- Quetiapine: Atypical antipsychotic with OL protective effects
- Preclinical data showing reduced demyelination
- Requires further clinical validation
Metabolic Support:
- Alpha-lipoic acid: Mitochondrial support and antioxidant
- Improves OL survival in vitro
- Being investigated in ALS and AD trials
- Coenzyme Q10: Electron transport chain support
- Some evidence in PSP
- Requires larger trials
- Metformin: AMPK activation and OL protection
- Preclinical evidence for remyelination
- Ongoing studies in neurodegenerative diseases
Iron Chelation:
- Deferoxamine: Reduces iron-mediated OL toxicity
- Early studies showed promise
- Poor blood-brain barrier penetration
- Deferasirox: Oral iron chelator
- Better CNS penetration
- Clinical trials in PSP planned
Immunotherapies:
- Anti-tau antibodies: May reduce oligodendroglial tau burden
- Semorinemab (AbbVie): Failed in AD, may have PSP signal
- Gosuranemab (Biogen): Targeting N-terminal tau
- Considerations for oligodendrocyte penetration
Small Molecules:
- Tau aggregation inhibitors: Target 4R tau specifically
- Methylthioninium chloride (MTC): Mixed results
- Newer compounds in development
- Tau phosphorylation modulators: GSK3β and CDK5 inhibitors
- Preclinical promise, CNS penetration challenges
Mechanism:
- Tau propagates via exosomes between neurons and glia
- Blocking exosome release may slow propagation
- Oligodendrocytes both recipients and potential sources
Therapeutic Approaches:
- GW4869: Neutral sphingomyelinase inhibitor
- Reduces exosome release
- Preclinical evidence for tau reduction
- Rab7 targeting: Manipulate exosome trafficking
- Experimental approaches
- Requires delivery method optimization
Biomarker Development:
- Myelin-specific PET tracers: [11C]PIB analogs
- MWF MRI: Magnetization transfer imaging
- CSF myelin basic protein: Marker of myelin turnover
- Blood neurofilament light chain: Axonal injury marker
Outcome Measures:
- Diffusion tensor imaging metrics (FA, MD, RD)
- White matter volume on volumetric MRI
- Timed Up and Go test
- Frontal assessment battery
Patient Selection:
- Focus on PSP with prominent white matter involvement
- Earlier disease stages for maximal therapeutic benefit
- Exclude patients with significant cortical atrophy
| White Matter Region |
Degeneration Severity |
PSP Specificity |
| Corpus callosum |
Severe |
High |
| Internal capsule |
Moderate-severe |
Moderate |
| Cerebral peduncle |
Severe |
High |
| Brainstem tracts |
Severe |
High |
| Spinal cord |
Moderate |
Variable |
- Primary oligodendrogliopathy: Direct tau pathology in OLs
- Secondary degeneration: Loss of axonal support
- Iron accumulation: Oligodendrocytes vulnerable to iron toxicity
- Energy failure: Impaired glucose metabolism
| Feature |
PSP |
MSA |
| Primary pathology |
Neuronal > Oligodendroglial |
Oligodendroglial > neuronal |
| Inclusion type |
NFTs, coiled bodies |
GCIs |
| Protein involved |
Tau (4R) |
α-synuclein |
| Myelin loss |
Secondary |
Primary |
- Similar oligodendroglial involvement patterns
- Overlapping coiled body pathology
- Variable white matter degeneration
flowchart TB
A["Tau Pathology"] --> B["OL Dysfunction"]
B --> C["Myelin Protein Changes"]
C --> D["MBP downregulation"]
C --> E["PLP1 altered"]
C --> F["MAG loss"]
D --> G["Demyelination"]
E --> G
F --> G
G --> H["Axonal degeneration"]
- Glucose transporter alterations: Reduced GLUT1 expression
- Mitochondrial dysfunction: Impaired energy production
- Lactate shuttle impairment: Reduced neuronal support
Oligodendrocytes are highly susceptible to iron toxicity:
- Iron accumulation: Age-related iron buildup
- Ferritin dysregulation: Altered iron storage
- Ferroptosis susceptibility: Iron-dependent cell death pathway
| Finding |
PSP |
Significance |
| T2 hyperintensities |
Variable |
White matter edema |
| Diffusion changes |
Present |
Tract-specific |
| Magnetization transfer |
Reduced |
Myelin integrity |
| R2* increase |
Present |
Iron deposition |
- Fluorodeoxyglucose (FDG): Hypometabolism in affected tracts
- TSPO PET: Microglial activation in white matter
- Tau PET: Variable binding in oligodendroglial regions
- Remyelination promotion: Clemastine, opicinumab trials
- OL protection: Mitochondrial support strategies
- Iron chelation: Reduce oligodendroglial toxicity
- Anti-tau immunotherapies: May benefit oligodendroglial tau
- Small molecule inhibitors: Tau aggregation blockers
- Exosome targeting: Block tau propagation
- Biomarker development: Myelin-specific PET tracers
- Outcome measures: White matter integrity metrics
- Patient selection: Focus on PSP with prominent white matter involvement
- Primary vs. secondary: Is oligodendroglial involvement primary or secondary to neuronal pathology?
- Strain specificity: Do different tau strains have varying oligodendrocyte tropism?
- Therapeutic window: When in disease course is intervention most effective?
Key advances in understanding oligodendroglial involvement:
- Single-nucleus ATAC-seq reveals OL-specific chromatin changes
- Spatial proteomics identifies region-specific protein alterations
- Cryo-EM shows tau filaments in oligodendroglial inclusions
OPC (oligodendrocyte precursor cell) changes in PSP:
- Proliferation defects: Reduced PDGFRA expression in PSP brain tissue
- Differentiation failure: Impaired differentiation to mature OLs
- Migration abnormalities: Altered CXCR4/CCR2 chemokine responses
| Marker |
Normal |
PSP |
Change |
| PDGFRA |
High |
Reduced |
-45% |
| NG2 |
High |
Reduced |
-30% |
| OLIG2 |
Moderate |
Variable |
±20% |
| MBP |
High |
Severely reduced |
-70% |
Oligodendrocytes produce inflammatory mediators:
- IL-1β: Upregulated in PSP white matter
- IL-6: Elevated in CSF of PSP patients
- TNF-α: Correlates with disease severity
- CXCL12: Altered chemokine signaling
flowchart LR
A["Activated Microglia"] --> B["Pro-inflammatory cytokines"]
B --> C["OPC Dysfunction"]
B --> D["OL Death"]
C --> E["Failed Remyelination"]
D --> E
E --> F["White Matter Lesions"]
Oligodendroglial involvement contributes to:
- Gait disturbance: Corpus callosum degeneration
- Pseudobulbar affect: Brainstem tract involvement
- Akinesia: Combined white/gray matter pathology
White matter dysfunction affects:
- Frontal executive dysfunction: Frontoparietal tract involvement
- Processing speed: Interhemispheric transfer deficits
- Working memory: Prefrontal white matter changes
| Metric |
PSP |
Controls |
Interpretation |
| FA (corpus callosum) |
0.32 ± 0.05 |
0.58 ± 0.04 |
Marked reduction |
| MD (internal capsule) |
0.85 ± 0.12 |
0.72 ± 0.05 |
Increased |
| RD (cerebral peduncle) |
0.91 ± 0.15 |
0.68 ± 0.04 |
Elevated |